TEL AVIV, Israel, June 6, 2013 /PRNewswire/ --
Inspiro Medical, a portfolio company of The Trendlines Group, recently completed a successful clinical trial for InspiromaticTM, its innovative, breath-synchronized, active dry powder inhaler.
The study, completed in May 2013 at Schneider Medical Center aimed to objectively assess, in a randomized, crossover, double blind study, the efficacy and safety profiles of formoterol (bronchodilator) treatment via the Inspiromatic in asthmatic children, compared to its delivery via a competitive inhaler already on the market.
30 children with asthma, aged 8-18, were randomly allocated to treatment with formoterol via the Inspiromatic inhaler or a competitive device.
The study met both primary and secondary endpoints. The results demonstrated superior results for of the Inspiromatic in pulmonary delivery of the active drug. Lung function test (FEV1) demonstrated a statistically significant improvement following formoterol delivery via the Inspiromatic. Moreover, the Inspiromatic was highly rated by patients. Successful delivery of the API was achieved even with patients with poor inhalation technique and even in low-flow inhalation rate.
"I'm very happy with the study results showing that the Inspiromatic achieved safety and efficacy," said Nimrod Kaufmann , CEO of Inspiro Medical. "This successful study will enable us to move to the next step in the company development and partner with pharmaceutical companies to develop drug-device combinations and also bring better therapy to patients with poor inhalation technique."
Despite the numerous aerosol delivery devices currently on the market, Inspiro Medical believes that their device can significantly improve effectiveness in deposing the necessary medication. Inspiromatic takes into account drug particle/droplet
|SOURCE Inspiro Medical Ltd.|
Copyright©2012 PR Newswire.
All rights reserved